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Abstract 
 
Firefly luciferase is a bioluminescent protein commonly used as a bioluminescent tag in 
biological studies and applications. However, because the protein is fairly large in size, 
it is sometimes larger than the molecules it is intended to measure and is therefore not 
a sufficient tag in smaller applications. The active site of firely luciferase is also not well 
understood, making it difficult to engineer the protein without affecting its bioluminescent 
activity. 
 
In this paper, we discuss the experimental methods of Reverse Protein Engineering: a 
bioengineering technology that reduces the size of a protein while retaining its original 
function. This involves subcloning a core section of the protein, attaching a DNA library 
to the core to achieve a large pool of randomized peptide variants, and screening those 
variants for any bioluminescent properties. Successful conduction of this technique 
would achieve two goals: 1) create a peptide alternative to resolve the protein’s current 
size limitations and 2) confirm the importance of specific amino acids that might 
contribute to the active site’s activity. 
 
Our experiments show that Reverse Protein Engineering can be done to decrease the 
size of Firefly Luciferase (550 amino acids) to a much smaller peptidic version of the 
protein (less than 80 amino acids). However, to determine successful function of the 
peptide variants, more research in screening the peptides for bioluminescent activity 
needs to be done. In addition, Reverse Protein Engineering with a different range of 
amino acids within the core could further the chances of achieving a successful 
bioluminescent peptide variant of firefly luciferase. 
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8. Introduction and Background 
 
8.1. Reverse Protein Engineering 
 
The technique of reverse protein engineering encompasses removing all non-essential 
amino acids that do not contribute to the catalytic function of the protein. The remaining 
essential amino acid sequence then has a random flanking sequence of 20 amino acids 
added to each side of the core region.  This creates a combinatorial library of millions of 
different proteins all with the same functional core region.  This library is then put 
through a stress test to determine which sequences are functional.  There are usually 
less than 10 functional proteins produced from the library and each of them is then 
tested to determine their attributes and sequence.  It is from this data that the smallest 
functional protein is determined.  The result of this is decreased steric hindrance at the 
molecular level which has the potential to increase the efficacy of the protein. 
 
8.1.1. Green Fluorescent Protein 
Existing work in Reverse Protein Engineering has previously been conducted on Green 
Fluorescent Protein (GFP). GFP is a protein also widely used as a visualization tag in 
biomedical research. However, because of its relatively large size, GFP’s use as a tag 
fused to target proteins is limited. Wild type GFP is composed of 238 amino acids and 
has a molecular weight of 26 kDa. The Reverse Protein Engineered peptide variant of 
GFP resulted to be 70 amino acids and was able to maintain a core identical to the 
function region wild type GFP. 
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Figure 1.  GFP core. Full length wild type Aequorea GFP (left) and the core peptide region C48-T97 
(right). Akido Umeda Dissertation 
 
 
 
8.2. Bioluminescence  
 
Bioluminescence is the emission of light by a living organism through a biochemical 
reaction. Organisms that possess bioluminescent properties include fireflies, beetles, 
glow worms, bacteria, fungi, and deep-sea fish.  In nature, bioluminescence serves 
organisms as a defense mechanism or device to lure prey. However, in the medical 
field, it is widely used in biomedical applications as a means for visualizing biological 
interactions on the molecular level. Some applications of bioluminescence in the 
biomedical field include in vivo imaging, activity assays, microarrays, and biosensors. 
 
Bioluminescent imaging is also deemed an important technology because of its 
advantages over fluorescent imaging. Fluorescence is another type of light emission 
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commonly used in biological research and is caused by energy excitation in a molecule 
from light. While both bioluminescence and fluorescence are widely used in scientific 
applications, bioluminescence is often considered better than fluorescence because the 
emission of light is intrinsically supplied by an enzymatic reaction, whereas fluorescence 
requires another source of light in order to emit energy. In addition, because of its 
enzymatic nature, bioluminescent reporters display an ultrasensitive detection capacity 
and have a wider dynamic range compared to fluorescent reporters.  
 
Fluorescent reporters, on the other hand, are susceptible to photo-bleaching, provide 
low quantum yields and have greater protein stability in cell-based assays compared to 
bioluminescent reporters, which make them less amenable for use as real-time 
reporters. Cellular components also have auto-fluorescent properties, which increase 
the non-specific background and decreases the sensitivity of fluorescent detection in 
cell-based assays. Conversely, cellular components have no inherent bioluminescence, 
allowing for greater sensitivity with bioluminescent assays. Thus, further research in 
bioluminescence is worth investing in to advance current and future applications within 
the biomedical field.  
 
 
8.3. Firefly Luciferase  
 
8.3.1. Background 
Luciferase is a bioluminescent protein that glows green upon reacting with its substrate 
luciferin. In current biological technologies, it is used to study a variety of biological 
applications, such as in-vivo imaging, cell proliferation assays, protein folding and 
secretion, and reporter gene assays. In nature, varying forms of luciferase exist in 
different types of organisms, such as firefly, bacteria, and marine animals. For the 
purposes of this project, firefly luciferase was studied because it is most commonly used 
in biological applications and is more commercially available.    
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8.3.2. Structure 
Firefly luciferase is comprised of 550 amino acids and is 63kDa in molecular weight. It 
also acts as a monomer, meaning that it can perform catalytic activity alone and without 
other subunits to assist in the reaction. The protein structure consists of two compact 
domains: a large N-terminal domain and a smaller C-terminal domain. Although it is 
currently not well understood, the active site of the enzyme is strongly suggested by 
multiple studies to be located in cleft between the two domains. The specific locations of 
the active site’s catalytic residues are also very much debated, but it is believed that 
majority of them lie within the N-terminal domain and possibly one or two within the C-
terminal domain. In order to study the active site using reverse protein engineering, the 
core regions used in this project will be extracted from the N-terminal domain where 
majority of the catalytic residues are proposed to reside.  
 
 
 
 
 
Figure 2.  Crystalline structure (left) and domain breakdown of Firefly Luciferase (right). 
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8.3.3. Mechanism 
In the presence of ATP and oxygen, firefly luciferase works by catalyzing the oxidation 
of its substrate, luciferin. This oxidation reaction forms an electronically excited state of 
the product, oxyluciferin. oxyluciferin returns to its ground state, photons of light are 
then emitted creating the bioluminescent effect of the reaction.  
 
 
 
Figure 3. Chemical reaction diagram of Firefly Luciferase oxidizing its substrate, luciferin.   
 
 
 
8.3.4. Catalytic Residues 
Currently, the catalytic amino acid residues within the active site of firefly luciferase are 
not well identified. Several studies have suggested a wide variety of possible catalytic 
residues that contribute to the catalytic function of luciferase. Table 1. provides a list of 
some of these catalytic residues and their proposed functions for catalytic activty. Our 
project aims to isolate a core region from wild-type firefly luciferase that encompasses a 
majority of these proposed catalytic residues.  
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Amino Acid Residue Location Function 
R218, F247, S347, A348 N-domain H-bonds with Luciferin 
G339, Y340, G341, A317 N-domain Holds adenine ring of 
ATP in place 
N422 N-domain H-bonds to ribose 
hydroxyl groups 
S199, K206 N-domain Chelate with B- and 
phosphate portion of 
ATP; activity in removal 
of PPi 
T343 N-domain Assists Lys529 
K529 C-Domain Responsible for lowering 
the energy of the 
transition state; likely 
assisted by Thr343 
 
Table 1. List of proposed catalytic amino acids, their respective locations, and hypothesized functions.  
 
 
8.4. Review of the Field 
 
8.4.1. Promega NanoLuc® 
In the current market for engineered luciferase, Promega has a product called 
NanoLuc®. NanoLuc® is a reduced form of Renilla luciferase, isolated from deep sea 
shrimp. Wild type Renilla luciferase is composed of 550 amino acid residues and has a 
size of 60.6 kDa. NanoLuc® is composed of 171 amino acids and has a molecular 
weight of 19.1 kDa.  The technology Promega used to achieve a reduced form of 
Renilla luciferase is much different from that of Reverse Protein Engineering. The 
resulting peptide variant also uses a synthesized small molecule as its substrate—the 
aim of Reverse Protein Engineering is to use a core region extracted from the original 
protein that can interact with luciferase’s natural substrate, luciferin. 
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8.5 Statement of project goal, objective and results 
 
The first goal our project hopes to achieve is to create a peptide alternative for wild-type 
firefly luciferase to resolve protein’s current size limitations. The successful reduction in 
size would allow the luciferase protein to be used as a tag molecule in small molecular 
studies and applications that its wild-type form is currently unfitting for. Specifically this 
smaller peptide form of luciferase could be used in very small microarrays, biosensors, 
and in-vivo imaging. 
 
The second goal of this project is to contribute to the characterization of luciferases 
active site and identification of its catalytic residues. We do this by isolating a core 
region that encompasses many of the currently proposed catalytic residues and 
determining if that isolated region can create a functional peptide that glows. If a peptide 
is successful, it would confirm that the included catalytic residues are important to 
catalytic function. 
 
The last goal of the project is to support the theory of a peptide world. This theory states 
that all current proteins today existed in the past as peptides and that the world once 
operated by peptide interactions alone before it became driven by protein interactions. 
Successful results from this project can show that a wild-type protein can exist and 
function as a peptide, thus supporting the theory of a previous peptide world. Again, the 
method in which all of these goals will be achieved is by reverse protein engineering. 
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9. Cost Analysis 
 
9.1 Budget Proposal 
 
 
Advisor: Jonathan Zhang <zzhang@scu.edu> 
 
This study was previously conducted using Green Fluorescent Protein where it was 
found that certain amino acids in the protein were unessential to the protein’s function. 
When these unessential amino acids were removed the protein was less of a 
hinderance to other proteins when used as a marker.  This year we plan to take the next 
step in this study by finding, and removing the nonessential amino acids in some 
therapeutic bacterial proteins.  The idea is that this will increase the efficiency of these 
enzymes which has huge potential in the biomolecular industry.   
 
This study is currently the only of its kind in the world as Professor Zhang is pioneering 
this field.  Increasing the efficiency of of an enzyme is essentially increasing the 
efficiency of the entire bio-molecular world.  These are the first steps towards opening 
an entirely new door in the future of medicine as it has the potential to create faster 
acting, more accurate, and more effective pharmaceutical drugs.   
 
Due to the various molecular and experimental materials needed to conduct this 
research, the total project budget proposal will amount to $1,500: 
 
Enzymes $500.00 
Reagents & assay kits $500.00 
Consumables (goggles, well plates, etc.) $500.00 
Total  $1,500.00 
 
Table 2.  This displays a basic breakdown of our proposed amount of money we needed 
 
 
This proposal was accepted and the project was granted a total of $1,500. 
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9.2. Breakdown of Expenditures 
 
 
Description/ Catalog # Date 
ordered 
Company Cost ($) 
pMV306hsp+FFlucWT 1/10/14 Addgene 85.00 
GoTaq(R) Flexi DNA Polymerase, 100u, 
M8291 
2/12/14 Promega 87.80 
Taq DNA Polymerase with Thermopol 
Buffer, 400 units, M0267S 
2/12/14 New England 
Biolabs 
89.34 
1.) Buffer QG (250ml), 19063 
2.) Buffer PE (100ml), 19065 
2/12/14 Qiagen  172.25 
1.) 218/247 F_BamHI 
2.) 247R_EcoRI 
3.) 218R_EcoRI 
1/16/14 ELIM 
BioPharm 
31.87 
BamHI_HF, 10,000 units, R3136S 3/17/14 New England 
Biolabs 
82.81 
DTT, 89148-136 2/13/14 VWR 169.09 
UREA 100g, 97061-914 2/13/14 VWR 21.42 
F_SpeI_iGFP, 174818-1 3/6/14 ELIM 
BioPharm 
28.55 
EcoRI_HF, 10,000 units, R3101S 3/7/14 New England 
Biolabs 
82.81 
T4 DNA Ligase, 100u, M1801 3/27/13 Promega 105.20 
1.) DNA Polymerase 1 Klenow Fragment - 
200 units, M0210S 
2.) NcoI-HF - 1,000 units, R3193S 
3/27/14 New England 
Biolabs 
150.24 
1.) Oligo Synthesis, 0.2, 81 
2.) Oligo Synthesis, 0.025, 14 
3.) Oligo Synthesis, 0.2, 83 
4.) Oligo Synthesis, 0.025, 14 
4/18/14 ELIM 
BioPharm 
118.28 
DNTP MIX [10 MM], 102703-686 4/9/14 VWR 76.57 
Total cost   $1300.7 
 
Table 3. This table provides a detailed breakdown of items purchased and their price 
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10. System Integration, Tests, & Results 
 
10.1 Experimental Methods 
 
10.1.1 Determination of Core Sequences 
The commercially obtained plasmid pMV306hsp+FFlucWT encodes the firefly luciferase 
gene cloned from pGL2-basic (Promega). We refer to this form of firefly luciferase as 
“wild-type” luciferase for the rest of this chapter unless otherwise noted. Upon 
conducting literature search, it was apparent that there are numerous active site 
residues that could assist with wild-type luciferase’s catalytic function. For the purposes 
of this project, we selected a peptide region of 48 amino acid residues, S199-F247 as 
the core of wild-type luciferase. For catalysis, S199, along with K206, are known to 
chelate with the phosphate portion of adenosine triphosphate (ATP) and assist in the 
removal of pyrophosphates. A218 and F247 are known to contribute hydrogen bonds to 
luciferin, the substrate. These functions are essential to catalysis, hence the reason we 
chose this region as our core. We refer to this core region as the 10K core for the rest of 
this chapter unless otherwise noted. 
  
10.1.2 Primer Design 
In order to isolate the 10K core from wild-type luciferase, the polymerase chain reaction 
(PCR) was employed. However, the first step was to design primers that incorporate the 
10K core. Also, since we are taking the 10K core and ligating it into our vector of choice, 
PET-28B, it is imperative to include restriction sites on both the forward and reverse 
primers. In our case, we chose restriction sites for BamHI and EcoRI, as our forward 
and reverse restriction sites, respectively. In addition, extra nucleotides flanking both 
ends of the restriction site were added in order to optimize digestion efficiency 
 
10.1.4 Library Flanking Sequences and Screening 
Upon successful ligation of the 10K core to the PET28-B vector, the next step was to 
ligate a library of 20 amino acid residues to the C-terminal domain of the 10K core. An 
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oligonucleotide library encoding 20 random amino acid residues by a codon NNK was 
purchased commercially (Elim Biopharmaceuticals). Using K at the third position of the 
codon eliminates two possible stop codons, TAA and TGA simultaneously allowing for 
the gene to transcribe all 20 possible amino acids. The complementary double-stranded 
oligonucleotide library was synthesized using the DNA Polymerase I, Large (Klenow) 
Fragment purchased commercially (New England Biolabs). This oligonucleotide library 
was then cloned at the C-terminus of the 10K core. The resulting plasmid was then 
transformed into BL21 E.Coli cells purchased commercially (New England Biolabs). 
  
Colonies from the library above were screened using a spray containing luciferin. None 
of the colonies emitted light. However, since there were fewer colonies than expected 
on the plates, it is a possibility that with more transformations and subsequent 
screening, there will be one colony that will emit light.  
 
 
10.2 Results 
 
The overall goal of our project was to decrease the size of Firefly Luciferase, but along 
the way we had several different protocols that had to have positive results in order for 
our end result to be possible. The first step of our project was to successfully isolate the 
core region from wild type Firefly Luciferase. We did in fact successfully isolate the core 
region and to check that we got exactly what we wanted we ran our PCR sample of the 
core through an electrophoresis gel. When compared to a 100 base pair ladder, the 
band in the gel, produced by the core, measured to be just under 150 base pairs. Since 
our core region was 144 base pairs long, we confirmed that we properly PCR isolated 
our core region out of the lucierfase gene. The next significant step was to sub clone 
this core region into a prepared Pet-28b vector. Again we were successful with this and 
achieved ligation of the core insert into the Pet-28b vector. In order to be one hundred 
percent sure we achieved successful ligation of our core insert, and not just self ligation 
of the vector, we sent out our newly made plasmid for sequencing. The sequencing 
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results gave us hard evidence to show us that we did in fact properly insert out core 
sequence into the Pet-28b vector. Below you can see the section of sequencing that 
contains our core in it. The core is highlighted and the rest of the unhighlighted 
sequence is the Pet-28b vector we used. 
 
 
 
 
Figure 4. This picture displays the sequencing of our successful cloning of the core sequence of 
luciferase into the Pet-28b vector. 
 
 
The next step for our project was to create our DNA combinatorial library to attach to the 
C-terminus of the core region we chose and isolated. We designed the sequence for 
this library and had it synthesized commercially since we do not have the resources at 
the to synthesize oligonucleotides. These oligonucleotides were double checked to be 
the right size by running them on a gel again and confirming they were only about 200 
base pairs long, and we had the right library to continue our project.  
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Once confirmed, we then ligated the library to the C-terminus of our core region to 
extend the sequence of the new protein, and give it more of a chance to fold properly 
and function. We were successful in ligating the library to the core because we were 
able to transform it into E.coli cells and plate colonies. If we did not get any colonies 
after transforming the E.coli then our library ligation would not have work. But this was 
not the case. We achieved successful ligation of our library and moved onto the last 
step of our project. This last step included, plating 10^8 different colonies and screening 
those colonies to see if any lit up, thus containing a proper functioning peptide variant of 
Firefly Luciferase. We unfortunately did not get any colonies to light up and show us a 
functioning peptide form of Firefly Luciferase. But there are many things that could have 
gone wrong, and we will discuss these in the following section. 
 
 
10.3 Discussion 
 
10.3.1 Analysis 
Unfortunately, we were not able to successfully reduce the size of firefly luciferase 
within the time we had for our project. This could have happened for a number of 
different reasons, and there are many things we could change to our experimental 
design that would increase our chances of successful reduction of the size of firefly 
luciferase. First off, we did not get to plate 10^8 colonies like we had planned too. We 
ran out of time to screen our colonies and were only able to plate and screen 10^4 
colonies. This means that half of our possible library combinations were not expressed. 
Therefore we still have a chance to get a properly functioning protein that glows. This 
process of screening takes a long time and it was difficult to try to get all this work done 
in such a short time period.  
 
Another factor that could have affected our results was the way we screened our 
colonies. There are no previous protocols for screening E. coli colonies containing 
luciferase, in the way we needed to screen them. We decided to mold the current 
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screening protocols to our specific needs, and ended up with a solution to spray over 
the plated colonies.  
 
Our protocol to screen the colonies included spraying the solution containing D-luciferin 
over the colonies and recording them for thirty minutes to see if there was any light 
emission. We had to wait thirty minutes because it can take up to thirty minutes for a 
molecule to pass through the membrane of the E.coli cells. Since there are no 
established protocols on how to screen E.coli colonies containing luciferase, we are 
unsure that this approach even works. This means that we could have possibly had a 
functioning firefly luciferase peptide variant, but it might not have responded to the spray 
solution we used. A possible problem with our screening method was the D-luciferin. 
We ran a control screening experiment with wildtype firefly luciferase to see if the spray 
solution would cause colonies with wild type luciferase to light up. We found out that not 
even wild type luciferase would light up with the D-luciferin, therefore we concluded that 
the D-luciferin substrate could have been bad from the beginning. 
 
 
10.3.2 Comparisons to predictions 
At the beginning of our senior design project, we predicted that we would be able to 
successfully reduce the size of wildtype Firefly Luciferase using reverse protein 
engineering protocol. In reality we almost accomplished this prediction, but fell a little 
short. This project was very advanced and difficult to perform in such a short time. Our 
group knew it would take a lot of work and effort to accomplish our task. Unfortunately 
even though we put in hours upon hours of work we did not achieve our prediction of 
reducing Firefly Luciferase’s overall size. We did however almost make it to our 
prediction. What I mean by this is that we achieved all the steps that were necessary in 
our project, in order to get to the end and see if we did get a new form of Firefly 
luciferase.  
 
We achieved successful PCR isolation of our core, successful sub cloning of that core 
into the Pet-28b vector, creation of our DNA combinatorial library, and ligation and 
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transformation of that library into E.coli cells. Without the success of these individual 
steps, we would not have been able to proceed and make it to the end of our project. In 
the end, we still had more colonies to plate so we are still unsure if we are were 
completely unsuccessful with the prediction that we would reduce the size of Firefly 
Luciferase. And even with that, we still were able to create and refine specific protocols 
of reverse protein engineering, and these protocols can be used in future projects of 
reverse protein engineering. 
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11. Summary and Conclusion 
 
11.1 Summary and Conclusion 
The main goal for our senior design project was to reduce the size of firefly luciferase 
using reverse protein engineering protocols. Over this past year our group has reached 
many necessary milestones along the road to reducing firefly luciferase’s size. These 
milestones include; successful PCR amplification of our selected luciferase core, 
successful cloning of our core luciferase region into the Pet-28b vector, successful 
creation of a DNA combinatorial library, and successful ligation of our DNA 
combinatorial library onto the C-terminal end of our cloned luciferase core. As a group, 
we had to achieve each one of the steps, one by one, in order to get to the end of our 
project and have a chance to reduce the size of firefly luciferase.  
 
Our group started by researching the key catalytic parts or the firefly luciferase protein. 
Once we had chosen the core of the luciferase protein, we were able to PCR isolate 
and amplify the core and clone it into our selected vector. With successful cloning, we 
had our desired plasmid containing the luciferase core, and could move on to creating 
the combinatorial library and attach it to the C-terminus of the core. The library was 
properly and successfully attached, and we then went to the last step of our project and 
screened colonies containing the new luciferase proteins. At this point we reached the 
final step of our project, but as mentioned before, unfortunately we were not able to 
produce a luciferase protein that folded properly and expressed bioluminescence. We 
screened thousands of colonies for a bioluminescent protein but were unable to confirm 
a positive glowing result. 
 
Although our experiments did not yield any of our predicted results we accomplished all 
of the steps of our reverse protein engineering protocols. The steps along the way were 
difficult and time consuming, but we were able to make it through each necessary step 
and successfully reach the end of our project, but did not achieve successful cloning of 
wildtype firefly luciferase 
  21 
 
By using reverse protein engineering protocols our group was able to attempt to reduce 
the size of the bioluminescence protein firefly luciferase. Due to the complexity of the 
experiments we were performing, our group was not able to successfully reduce the 
size of firefly luciferase. There are many factors that complicated this project and made 
it very difficult to achieve our end goal such as protein kinetics, substrate-protein 
interactions, and protein folding. These topics illustrate the complexity of our project 
because they all had to be considered when we altered our experiments for the size 
reduction of firefly luciferase. 
 
11.2 Future Work 
Our project had several variable factors, and for that reason there are protocols that can 
be altered to improve the possibilities of reducing the size of firefly luciferase in future 
work. Some areas that can possibly be changed or improve to alter the result of this 
project are; investigate and increase the size of the chosen core, chose different 
restriction enzymes for cloning of the core and sub-cloning of the library, use a different 
vector, create an alternate screening method, and research more about the D-luciferin 
substrate interaction with luciferase. Overall, several things could be changed and 
explored more, and with more time and future work this project can yield a smaller sized 
firefly luciferase. 
 
11.3 Reflection/ Lessons learned 
Our group started this project with the expectation of reducing the size of wildtype firefly 
luciferase, but we were unfortunately unable to achieve our final goal. Even though we 
did not achieve a successful end goal with our experiment, we still gained many 
valuable experiences and methods from our project. Through this project we were able 
to gain valuable laboratory skills that are applicable to several industry jobs around the 
country. We were faced with several challenges along the way through our experiment, 
but with hard work and dedication we were able to work as a group and move pass the 
challenges that arose. One example is the difficulty we had attempting to clone our 
luciferase core into the Pet-28b vector. Our group had several failed attempts at this 
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step in our experiment, and it took some extra research and late nights in the lab to 
finally get passed the problem and achieve successful cloning of our core. Once we 
achieved successful cloning we did not have another problem with it in the entire 
project. This work pushed us to critically think at a level higher than regular class, and it 
was a great learning experience applicable to future jobs. This project also taught us 
how to work as a team. Working as a group of four can be tough due to coordination of 
everyone’s schedules and ideas. We were able to successfully work together, 
cooperating and synthesizing our ideas and time in order to complete the steps of our 
senior design project. Our group felt that we worked well together and were satisfied 
with the work we accomplished for our project, regardless of the end result. For future 
students, we suggest to work proactively on senior design projects to allow for a 
prepared timeline that can accommodate for any setbacks, troubleshooting, and 
material delivery times. Students should also expect to allocate a large amount of their 
time working in the lab if they wish to obtain the best possible results from their projects, 
as time in the lab is time well spent for success. 
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12. Engineering Standards 
 
12.1 Ethics 
 
For our senior design project, it is important that we conduct ourselves in an ethical 
manner. As future members of the engineering profession, we are expected to learn 
and exhibit the highest levels of honesty and integrity. It is crucial that we act with 
honesty and integrity throughout all stages of our senior design project—from inception 
to completion. Our group must act ethically with each other, as well ensure that we act 
ethically with everyone involved so that the end users of our product do not encounter 
any issues. 
 
As the product from our senior design project has the potential to be used for medical 
purposes, our ethical responsibility to the potential users of our product is immense. Our 
project not only looks to design a single more efficient protein; the technology used also 
has the potential to open up entirely new doors in the medical industry as we are 
pioneering this enzymatic manipulation technique. With a potential like this we have a 
great responsibility to conduct our research with the upmost ethical integrity to ensure 
that we are able to gain the most we can out of this project.   
 
 
12.2 Environmental 
 
Our Project was environmentally friendly, and we did take the environment into 
consideration with our project. Although our senior design project was primarily working 
with biological substances that produce no toxins or pollution, we still had to keep in 
mind disposing the hazardous waste properly to ensure no damage to the environment. 
Since we are working with bacteria we created biohazard waste, that needs to be 
properly disposed of. In specific our team would thoroughly bleach any culture plate 
containing E.coli bacteria to ensure the E.coli was dead before we disposed of it in the 
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bio-hazard trash, which gets collected weekly and sent out to be burned. If we did not 
bleach the plates, the E.coli bacteria could spread and mutate into a new airborne virus 
that could be potentially harmful to humans. Therefore it is important to bleach all the 
plates before we throw them out, so we protect the environment from any damaged that 
could be caused by a mutated E.coli strain. Since the bio-hazard trash that is burned is 
mainly just dead E.coli cells and culture media, little to no pollution is created in the 
disposal of the bio-hazard trash. Overall, our team considered environmental issues 
when disposing of our experiments waste, and were able to prevent any harm done to 
the environment. 
 
 
12.3 Health and Safety 
 
Our safety for the purposes of our project, it is imperative that we take the utmost care 
in ensuring our safety and the safety of others we share the lab with. Prior to beginning 
our lab work, we have taken lab safety training courses sponsored by Santa Clara 
University. While in the laboratory we must wear proper personal protective equipment, 
such as gloves, goggles, and lab coats, at all times. Lab benches should not be 
cluttered with materials, and should be wiped down after lab work with ethanol. We 
should also know where the eye wash and shower locations are and how to operate 
them if need be. We as a group have been acting  
in accordance with Santa Clara's safety regulations thus far 
 
 
12.4 Manufacturability 
 
Manufacturability of the product is a great consideration in the research of reverse 
protein engineering. Therapeutic protein molecules are manufactured by genetically 
modifying cells of microorganisms—typically, E.coli—and using those cells as a vehicle 
to naturally synthesis the desired protein. To genetically modify the cells to include the 
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DNA sequence coding for the protein, the protein’s DNA sequence needs to be PCR 
amplified. Generally, larger biomolecules take more time, starting materials, and energy 
to be PCR amplified, and thus can be more difficult to manufacture in large masses. 
Because reverse protein engineering aims to create smaller biomolecules, it costs a 
shorter amount of time and less resources to be amplified and makes manufacturability 
of the engineered product easier to conduct. With this in mind, our team chose a protein 
that is commonly used, would benefit from being reduced in size, and whose 
manufacturability would be simple and straightforward. Because the ultimate goal of the 
research in reverse protein engineering would be to expand into pharmaceutical 
purposes, manufacturability and reproducibility of a successful product is key. 
Fortunately, reverse protein engineering currently appears to improve the manufacturing 
process of future peptidic biomolecules.  
 
 
12.5 Social 
 
The progression of research in reverse protein engineering is invaluable to the social 
community as it has the ability to open up new doors in the field of pharmaceuticals.  
The doors that will open will create new lines of drugs that have the potential to be more 
efficient and effective than any existing drugs on the market.  This is can lead to drugs 
with less side affects that could negatively affect the patient's quality of life.   
Often times people are backed into a corner where they must take a drug because the 
main affect of it is that it will let them live.  However, the side affects of these drugs can 
deteriorate the quality of a person's life to the point where the gain or barely more than 
the sacrifice.  The potential to create drugs without or even with less side affects 
through the technique of protein engineering renders not progressing this area of 
research unethical.  People owe it to each other in this world to help each other as that 
is how we have progressed the world into what it is today. The field of reverse protein 
engineering has the ability to help others which means it is only just to continue this 
research with the hopes that someday it will benefit humanity as a whole.   
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14. Appendix A 
 
 
 
 
Figure A1. This figure illustrates the Pet-28b vector 
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Figure A2. This figure illustrates our original wild-type plasmid containing the firefly luciferase gene 
  
 
